In this video, we are going to be talking about the top five penny stocks for October 2020 and the reason that we include penny stocks in our videos is because penny stocks have these huge catalysts such as Fda approval decisions, phase data releases, and insider trading activity. And if you know about these events ahead of time, you can then go and trade off them. Penny stocks are quite a powerful instrument, but don't take my word for it, Let's go ahead and review last month's picks. Okay, so in last month's Top 7 penny Stocks video, we started with each on Eton, was due for an Fda approval decision for two of their drugs, and we made the connection that because they had a previous history of spiking on Fda catalysts, that it would be worth playing if we got pre-runs or post runs.

it ran up to 10 21. Next we spoke about Fbi. Oh, Now Fbi Oh was due for an Fda approval decision on October 10th and we called this out way back then because it has a long-term consistent uptrend and thus was more likely to pre-factor in the decision ahead of time. Well, that's exactly what happened and it ended up running from our call-out price at 323 to 486.

it cooled down and now we are in a new area of pre-anticipatory running up to the decision. Next, we spoke about Clvs. We talked about how they were going to be presenting their early phase data and how we were going to need to play pre-anticipatory running. Clvs was a very swell play.

We spoke about it when it was trading at 5 14 and it ran up to 8 20 right before the event. That's a 60 increase on a swing position and obviously we as traders can't catch all the move. but you can see the value of following Catalysts and also the value of not just holding and hoping because look, it sold off afterwards. Next we spoke about Aqst and how it was due for an Fda approval decision on September 27th.

In that video, I explained that I thought the chart was gross and that frankly, I'm a cheap dude and I want to get a better deal so that we can play a pre-anticipatory run and that is actually what happened. We got a pretty swell pre-anticipatory run after Aqst found a bottom at 7ish and it ran up to 947. sold off again and once again ran up this right. here is a traders paradise.

But then the decision came out and it got beat down. And this is why you do not hold through Catalyst. Okay, next, Miso. Not not this miso, but this miso.

We spoke about how Miso was due for Fda approval at the end of September and how it has a history of huge reactions to Fda decisions like last time when it sold off rapidly and then recovered. Once it found the bottom a few days later, it actually got a pretty decent amount of pre-anticipatory running. But then when the decision was made, Miso got beat down like a rabid dog. But since every reaction is an overreaction, we got a beautiful nearly 20 run the next day next Lpcn.

So we spoke about how Lpcn was due for an Fda approval, but that we'd want to make sure that we got a good deal before playing it. It ended up finding a bottom somewhere around 122 and then running up to 170ish, but this was a tough play. Sure, there was a lot of pre-anticipatory running, but the Fda kept toying with us and still hasn't released their decision. And this is really what sucks about the Fda this year.

A lot of the time they just don't come out with the decision, but still getting a good deal and writing. Pre-anticipatory running was still very powerful, and that's why you need to make sure that you're attacking these the right way. Lastly, we spoke about Mnk, so this was a pretty bad pick Charlie, and to be fair, it did run up like 10 to 15 mid-september but this was just part of a broader downtrend and it ended up getting railroaded over anyways. But anyways, folks, one of the things that I want to get through to you and get into your mind this month is that you need to stop trading like a peasant when you randomly buy a stock.

What you're doing is getting on your knees and begging, looking up at the stock market and saying please sir, please, can I have some more? Can you please give me some crumbs? No folks, we're not stock market peasants, so stop acting like a stock market peasant. At Ziptrader, we trade like spoiled brats. That means having a plan, learning what to do. That means controlling your risk for when that plan inevitably doesn't work.

There's a huge difference between a calculated position and then just simply gambling and hoping that it works out. But anyways, folks, before we get into this month's top five penny stocks video, the only thing that I ask in return is that you hit that ravishing like button. You know that a lot of work goes into researching and identifying these opportunities for you and the only thing that I really ask is just one ravish. And lastly, quick plug for folks who are wondering what broker to trade these stocks on.

We always like to send new traders over to Weeble and you will get two free stocks if you sign up and deposit with our link in the description below. Now we like Weeble because it's a very powerful platform. It has tons of great scanning capabilities. We just talked yesterday about how I find a ton of my opportunities by looking at the pre-market gainers and how I find a ton of opportunities by looking at their hot industry breakdown that identifies sectors that are running up hot each and every single day.

But in any case, if you would like two free stocks, if you're wondering what broker did trade and if you want a powerful broker, well Weeble is in the description below, you can go ahead and click that link. Okay, so to start Fbi. Oh, now Fbio is due for their Fda approval decision on October 10th. This is for their tramadol injection for post-operative pain.

and if you recall, we spoke about playing pre-anticipatory runs in Fbio way back here in last month's video. But now that we've shown that Fbi Oh not only has the ability to pre-anticipatory run this much and now has given us a lot of new upside since it sold off, now there is a ton more opportunity if we get a new pre-anticipatory run or post-reaction run. And if you look at the monkey analyst price targets, what we are seeing is 92 percent of Upside. Now you know how I feel about the monkeys.

I like them as far as I can throw them and I throw them far. but this gives you an idea of how much hype is underneath the surface if this does indeed get approved. And the pain management injection in question is available in many other countries in Europe and throughout the world, but not yet in the United States and studies have shown that it is very effective for pain management and even in the Uk you can use it on kids as young as 12 years old. So again, not crazy to think that this might get approved this month, but at the same time will? you Never really know with the Fda, but doesn't matter.

We can play off pre-runs and post runs and stay out if we get neither. Okay, next Sppi Now Sppi will be due for their Fda approval decision on October 24th for their drug Rolantis. Now a little bit of background spectrum. Pharma is a Cancer Care stock and it has three different major drugs in their pipelines.

Now, this doubling in share price back in July happened when it came out that Sppi saw positive results for one of these treatments. But now that we are in the actual running up to the approval decision and not just phase data, we have the potential to have a run like this and perhaps even more. And monkeys are giving it a price target to twelve dollars, which is a casual 181 percent of upside. That being said, the thing to keep in mind here is that unlike a lot of these plays, the long-term context of Sppi is really nice.

Sppi had gotten beaten down back at the end of 2019, losing half of its share price when one of their phase data results didn't come back as it had planned it to. But because of that, we have an interesting situation because now we can afford to double in price and still not even be where we were trading at pre. this negative result and I'm not saying that it's going to double in price, but what I'm saying is there's a lot of upside and not as much downward potential since we are also in this consistent uptrend towards these pre-beat down prices. Okay, next Cola Now Kala will be due for their Fda approval decision on October 30th.

Kala had run up massively towards the beginning of the summer, but then sold off. And since it's had these two periods of uptrends that followed the first of which wasn't able to change the direction of the stock and the second of which we are still watching, analysts are ranking it at 134 of Upside. Paula is now trading a decent amount below its year highs, and these two uptrends tell me that Kala is attempting to reverse its downtrend and a catalyst like an Fda approval decision is something that could ultimately make that happen. Again, I don't want to sound like a dead horse, but trading pre-anticipatory runs or post runs on these are the way to go.

And in terms of the fundamentals, analysts are estimating that we're going to see about 223 million in revenue for this company in 2026 if this gets approved. And that's a big deal considering that Kala's current revenue is around 10 million dollars. So lots of hype potential here to say the least. Admp Now Admp is due for an Fda approval decision on November 15, 2020 and the reason that we are talking about it now is because this Fda approval was originally slated for November 25th, 2019.

And back then in this period leading up to that decision, it ran from 50 cents to 141. but then with the delay it got totally destroyed. But now one year later, we are starting to see some pre-anticipatory runs and it's very likely that we get another show before the next decision. But again, if you notice, it didn't matter that it got delayed back here because the opportunity was in the pre-run so you won't be surprised that you want to play the pre-run and the post run.

Okay, and lastly, Lpcn. Now the Fda has been a little slow salamander when it comes to Lpcn. They originally set their date for their low testosterone therapy to August 28th and it ran up massively in anticipation, but then got delayed and the downtrend was accelerated. We are now trading at half the price we were when investors were factoring in a decision and still no decision has been made.

If you look at Lpcn's regulatory update, the company said that the Fda needed more time to review this and they expect it to be completed in the next few weeks, but this was back at the end of August. It's now October October, so it's expected that we'll see at least some update this month, and that will be very important for us as there's a ton of upside just to get back to when investors were expecting a decision. so definitely worth watching. Even if we don't get a decision, there's probably going to be some sort of activity here.

Okay folks, Well, there you have it. Just make sure to trade like a spoiled brat this month. Always have a plan, always make sure that you're getting in at good setups, and of course cross your arms and scream i don't want it if you find yourself stuck in a bad position And of course if you have any questions, feel free to reach out to us in the comments section below or join us on Zip Trader Circle. On Zip Trader Circle, we also post our nightly watch list every single night by the nature of being nightly.

And lastly, if you'd like to be forged into a trader, we do offer Ziptraderu which is 50 off if you type in coupon code stayhome2020. On Ziptraderu we walk you through everything that we believe you need to know in order to be a trader, and of course we don't just leave you with that. We also give you our morning briefings each and every single morning as part of being a member and you can also work with us in our private chat which is pretty awesome because you get to work with everybody else that's in the same program as you. but of course it is up to you to decide whether or not we are a good fit for you and your trading goals.

Anyways, folks have a good day and I'll see you in the next video.